Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism

Drug Metabolism and Disposition

Volumn 31, Issue 1, 2003, Pages 98-107

  Sauer, John Michael ^a   Ponsler, G Douglas ^a   Mattiuz, Edward L ^a   Long, Amanda J ^a   Witcher, Jennifer W ^a   Thomasson, Holly R ^a   Desante, Karl A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYATOMOXETINE; ATOMOXETINE; CARBON 14; CYTOCHROME P450 2D6; DRUG METABOLITE; NORADRENALIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOTRANSFORMATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; URINARY EXCRETION;

ADULT; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; HUMANS; MALE; MIDDLE AGED; PROPYLAMINES;

EID: 0013499111     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.1.98     Document Type: Article

References (10)

1. Evans DAP, Maghoub A, Sloan TP, Idle JR, and Smith RL (1980) A family and population study of the genetic polymorphism of the debrisoquine oxidation in a white British population. J Med Genet 17:102-105.
2. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, and Lemberger L (1985) Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 25:296-301.
3. 3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 157:203-206.
4. Guengench FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism and Biochemistry (Ortiz de Montellano PR, ed) pp 473-535, Plenum Press, New York.
5. Long AJ, Witcher JW, Smith BP, Sauer JM, Heiligenstein JH, Cohen L, Wilens J, Rea J, Biederman J, and Spencer T (1999) Single-dose and steady-state pharmacokinetics of tomoxetine in pediatric ADHD patients. PharmSci Suppl 1:Abstract 1073.
6. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T and the Atomoxetine ADHD Study Group (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:E83.
7. Ring BJ, Gillespie J, Eckstein JA, and Wrighton SA (2002) Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30:319-323.
8. Steiner E, Bertilsson L, Sawe J, Bertling I, and Sjoqvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44:431-435.
9. Wolf CR and Smith G (1999) Chapter 18. Cytochrome P450 CYP2D6. IARC Sci Publ (Lyon) 148:209-229.
10. Wong DT, Threlkeld PG, Best KL, and Bymaster FP (1982) A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 222:61-65.